Weight change in the management of youth-onset type 2 diabetes: the TODAY clinical trial experience

Pediatric Obesity

Volumn 12, Issue 4, 2017, Pages 337-345

  Marcus, M D ^a   Wilfley, D E ^b   El ghormli, L ^c   Zeitler, P ^d   Linder, B ^e   Hirst, K ^c   Ievers Landis, C E ^f   van Buren, D J ^b   Walders Abramson, N ^d  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c GEORGE WASHINGTON UNIVERSITY   (United States)

^d University of Colorado Denver and Children s Hospital Colorado   (United States)

^e NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^f CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

behavioral weight control; cardiometabolic risk; lifestyle; type 2 diabetes

Indexed keywords

METFORMIN; METFORMIN PLUS ROSIGLITAZONE; ANTIDIABETIC AGENT; DRUG COMBINATION; GLUCOSE BLOOD LEVEL; THIAZOLE DERIVATIVE;

ADOLESCENT; ARTICLE; BODY WEIGHT MANAGEMENT; CARDIOMETABOLIC RISK; CAUCASIAN; CHILD; CLINICAL PROTOCOL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; FEMALE; HEALTH PROMOTION; HISPANIC; HUMAN; LIFESTYLE; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ONSET AGE; ORAL GLUCOSE TOLERANCE TEST; OUTCOME ASSESSMENT; PATIENT ATTITUDE; PATIENT EDUCATION; PHYSICAL ACTIVITY; PRIORITY JOURNAL; SCHOOL CHILD; SYSTOLIC BLOOD PRESSURE; WEIGHT CHANGE; WEIGHT CONTROL; ANTHROPOMETRY; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DRUG COMBINATION; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TREATMENT OUTCOME;

ADOLESCENT; ANTHROPOMETRY; BLOOD GLUCOSE; BODY WEIGHT; CHILD; DIABETES MELLITUS, TYPE 2; DRUG COMBINATIONS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; LIFE STYLE; MALE; METFORMIN; RISK FACTORS; THIAZOLES; TREATMENT OUTCOME;

EID: 84968690706     PISSN: 20476302     EISSN: 20476310     Source Type: Journal    
DOI: 10.1111/ijpo.12148     Document Type: Article

References (21)

1. Zeitler P, Hirst K, Pyle L, et al. A clinical trial to maintain glycemic control in youth with type 2 diabetes. N Engl J Med 2012; 366: 2247–2256.
2. TODAY Study Group. Effects of metformin, metformin plus rosiglitazone, and metformin plus lifestyle on insulin sensitivity and β-cell function in TODAY. Diabetes Care 2013; 36: 1749–1757.
3. Study Research Group TODAY, Zeitler P, Epstein L, Grey M, et al. Treatment options for type 2 diabetes in adolescents and youth: a study of the comparative efficacy of metformin alone or in combination with rosiglitazone or lifestyle intervention in adolescents with type 2 diabetes. Pediatr Diabetes 2007; 8: 74–87.
4. Kuczmarski RJ, Ogden CL, Guo SS, et al. 2000. CDC Growth Charts for the United States: methods and development. Vital Health Stat 11 2002; 246: 1–190.
5. Flegal KM, Wei R, Ogden CL, et al. Characterizing extreme values of body mass index-for-age by using the 2000 centers for disease control and prevention growth charts. Am J Clin Nutr 2009; 90: 1314–1320.
6. TODAY Study Research Group. Design of a family-based lifestyle intervention for youth with type 2 diabetes: the TODAY study. Int J Obes (Lond) 2010; 34: 217–226.
7. Kalarchian MA, Levine MD, Arslanian SA, et al. Family-based treatment of severe pediatric obesity: randomized, controlled trial. Pediatrics 2009; 124: 1060–1068.
8. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405–412.
9. TODAY Study Group. Rapid rise in hypertension and nephropathy in youth with type 2 diabetes: the TODAY clinical trial. Diabetes Care 2013; 36: 1735–1741.
10. TODAY Study Group. Lipid and inflammatory cardiovascular risk worsens over 3 years in youth with type 2 diabetes: the TODAY clinical trial. Diabetes Care 2013; 36: 1758–1764.
11. Grey M, Schreiner B, Pyle L. Development of a diabetes education program for youth with type 2 diabetes. Diabetes Educ 2009; 35: 108–116.
12. Kendall D, Vail A, Amin R, et al. Metformin in obese children and adolescents: the MOCA trial. J Clin Endocrinol Metab 2013; 98: 322–329.
13. Luca P, Dettmer E, Khoury M, et al. Adolescents with severe obesity: outcomes of participation in an intensive obesity management programme. Pediatr Obes 2015; 10: 275–282.
14. Savoye M, Shaw M, Dziura J, et al. Effects of a weight management program on body composition and metabolic parameters in overweight children: a randomized controlled trial. JAMA 2007; 297: 2697–2704.
15. Danielsson P, Kowalski J, Ekblom O, Marcus C. Response of severely obese children and adolescents to behavioral treatment. Arch Pediatr Adolesc Med 2012; 166: 1103–1108.
16. Johnston CA, Tyler C, Palcic JL, Stansberry SA, Gallagher MR, Foreyt JP. Smaller weight changes in standardized body mass index in response to treatment as weight classification increases. J Pediatr 2011; 158: 624–627.
17. Knop E, Singer V, Uysal Y, et al. Extremely obese children respond better than extremely obese adolescents to lifestyle interventions. Pediatr Obes 2015; 10: 7–14.
18. Schwimmer JB. Clinical trials for adolescent obesity: cooking up an alphabet stew of what to do. JAMA Pediatr 2013; 167: 391–393.
19. Linder BL, Fradkin JE, Rodgers GP. The TODAY study: an NIH perspective on its implications for research. Diabetes Care 2013; 36: 1775–1776.
20. Constantino MI, Molyneaux L, Limacher-Gisler F, et al. Long-term complications and mortality in young-onset diabetes: type 2 diabetes is more hazardous and lethal than type 1 diabetes. Diabetes Care 2013; 36: 3863–3869.
21. Springer SC, Silverstein J, Copeland K, et al. American academy of pediatrics: management of type 2 diabetes mellitus in children and adolescents. Pediatrics 2013; 131: e648–664.